SS&H Financial Advisors Inc. trimmed its position in Merck & Co., Inc. (NYSE:MRK – Get Rating) by 1.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,835 shares of the company’s stock after selling 532 shares during the quarter. Merck & Co., Inc. accounts for 2.1% of SS&H Financial Advisors Inc.’s holdings, making the stock its 10th biggest holding. SS&H Financial Advisors Inc.’s holdings in Merck & Co., Inc. were worth $4,635,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of MRK. Landmark Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the first quarter valued at about $25,000. Joseph P. Lucia & Associates LLC acquired a new position in Merck & Co., Inc. during the 1st quarter valued at about $25,000. Front Row Advisors LLC boosted its holdings in Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after acquiring an additional 160 shares during the last quarter. Okabena Investment Services Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Finally, Western Pacific Wealth Management LP purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $29,000. 73.33% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have commented on MRK. SVB Leerink raised their target price on Merck & Co., Inc. from $105.00 to $109.00 and gave the stock an “outperform” rating in a research note on Monday, September 12th. Erste Group Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Atlantic Securities lifted their price target on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Morgan Stanley upped their price target on Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Finally, Cowen lifted their target price on Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a report on Monday, June 27th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.28.
Merck & Co., Inc. Stock Performance
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.’s revenue was up 28.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.31 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 7.33 earnings per share for the current year.
Merck & Co., Inc. Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a $0.69 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 annualized dividend and a yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is 42.27%.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.